PolyPeptide, the contract peptide manufacturer, has attracted buyout interest as its operational turnaround builds credibility with potential acquirers. The company, which provides outsourced peptide synthesis and manufacturing services to pharmaceutical clients, appears to have stabilized sufficiently to draw serious acquisition attention. Peptide-based therapeutics have seen sustained demand growth, driven by the commercial success of GLP-1 receptor agonists and broader adoption of peptide drugs across metabolic, oncology, and rare disease indications. Contract development and manufacturing organizations in the peptide space carry strategic value given high barriers to entry, specialized equipment requirements, and the regulatory complexity of peptide synthesis at scale. For PolyPeptide, buyout interest signals that prospective acquirers view the turnaround as durable rather than cosmetic, a key threshold for deal credibility. Investors and analysts should track whether formal processes are initiated, which strategic or private equity players engage, and whether any bid reflects a premium to current trading levels. Any deal would also reprice comparable CDMO assets in the peptide segment.
Flipkart will launch a food delivery pilot in Bengaluru by mid-August, charging restaurants a 10-11% commission compared to the 25-35% levied by Swiggy and Zomato. The move targets growing restaurant discontent with incumbent platforms and aims to drive daily engagement across Flipkart's 500 million registered users.
Maruti Suzuki crossed two lakh domestic units in July 2026 for the first time, recording 42.4% year-on-year growth. Total sales including exports and OEM supplies reached 2,41,421 units, with all passenger vehicle segments posting gains.
Air India's net loss more than doubled to ₹22,238 crore in FY26, prompting Tata Sons chairman N Chandrasekaran to extend the Vihaan.AI turnaround timeline from five years to as long as a decade.
UpGrad's all-stock acquisition of Unacademy, valued at Rs 1,955 crore, is set to close within three weeks after CCI clearance and near-complete investor sign-offs. The deal combines upGrad's upskilling business with Unacademy's test prep and medical education platforms, with Gaurav Munjal staying on as CEO.
